Beyond rNPV Valuations

Many valuation purists believe that a risk-adjusted net present value (rNPV) is the be-all and end-all of the value of a pharmaceutical asset. After all, it captures all the best insights into future...
Learn More

For pharma & biotech, what's the value of a valuation?

When a client approaches us about conducting a valuation for them, our first question is always: why? If, for example, the reason is to help support them in a partnering negotiation, we proceed...
Learn More

What Happens to Pharma Valuations as Interest Rates Rise?

Everyone familiar with the risk-adjusted net present value method (rNPV) knows automatically that valuations decrease as the discount rate increases. This is indeed a fundamental tenet of the...
Learn More

Pipeline asset valuation: garbage in – garbage out

Methods of valuing pharmaceutical development-stage assets have been a perennial talking point for decades, and the advantages and disadvantages of each have been covered in numerous publications....
Learn More

Pharma Valuations: When to Use Incidence and/or Prevalence

Many would agree that input assumptions are the most important part of a pharma or biotech portfolio valuation. Of these, one particularly critical assumption is the addressable patient population,...
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.